{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:46:09Z","timestamp":1792691169070,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To evaluate long-term changes in weight and metabolic parameters in people with HIV-1 (PWH) initiating first-line antiretroviral therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Analysis of two Phase 3, randomized, double-blind, active-controlled trials (1489: NCT02607930; 1490: NCT02607956). PWH received bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) or dolutegravir (DTG)-based treatment (Study 1489: dolutegravir\/abacavir\/lamivudine [DTG\/ABC\/3TC]; Study 1490: DTG\u2009+\u2009F\/TAF) for 144 weeks, followed by B\/F\/TAF (96-week open-label extension up to Week 240). Weight and metabolic parameters were assessed through Week 144 by randomized treatment assignment. Weight changes by baseline viral load and CD4 count were evaluated in PWH receiving B\/F\/TAF from baseline through Week 240. Multivariate modeling explored baseline factors associated with absolute weight and weight change through Week 240 and weight gain\u2009\u2265\u200910% at Week 240.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median weight and body mass index (BMI) increased over time with B\/F\/TAF (<jats:italic>n<\/jats:italic>\u2009=\u2009628), DTG\/ABC\/3TC (<jats:italic>n<\/jats:italic>\u2009=\u2009315), and DTG\u2009+\u2009F\/TAF (<jats:italic>n<\/jats:italic>\u2009=\u2009325). There were no significant differences in change in weight or BMI between the B\/F\/TAF and DTG\u2009+\u2009F\/TAF groups or between the B\/F\/TAF and DTG\/ABC\/3TC groups at Week 144 in either trial, nor were there differences in other metabolic parameters, including incidence of treatment-emergent diabetes mellitus and hypertension through Week 144. Among PWH receiving B\/F\/TAF (baseline through Week 240), weight increases were greatest soon after initiating antiretroviral therapy (i.e., Weeks 0\u201348), particularly in participants with baseline viral load\u2009&gt;\u2009100,000 copies\/ml and\/or CD4 count\u2009&lt;\u2009200 cells\/\u00b5l. In multivariate modeling (B\/F\/TAF pooled data), lower baseline CD4 count and higher HIV-1 RNA were associated with lower baseline weight and greater weight gain, but not absolute weight, from Week 48 through Week 240.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>No significant difference in weight change from baseline to Week 144 was found between bictegravir and DTG, or between B\/F\/TAF and a non-TAF-containing regimen, in these two randomized trials. Furthermore, weight gain following treatment initiation was greatest in the first year of treatment and most pronounced in individuals with more advanced HIV at baseline, supporting the hypothesis that weight gain following initial treatment is linked to a \u201creturn to health\u201d in people with advanced HIV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12981-025-00732-w","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T14:37:03Z","timestamp":1744036623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term metabolic changes with bictegravir\/emtricitabine\/tenofovir alafenamide or dolutegravir-containing regimens for HIV"],"prefix":"10.1186","volume":"22","author":[{"given":"Eric S.","family":"Daar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Sax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Hagins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Workowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Deaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cal","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharline","family":"Madera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-3423","authenticated-orcid":false,"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"2","key":"732_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/pathogens11020197","volume":"11","author":"NW Cummins","year":"2022","unstructured":"Cummins NW. Metabolic complications of chronic HIV infection: a narrative review. Pathogens. 2022;11(2):197.","journal-title":"Pathogens"},{"issue":"2","key":"732_CR2","first-page":"101","volume":"13","author":"RJ Henning","year":"2023","unstructured":"Henning RJ, Greene JN. The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV. Am J Cardiovasc Dis. 2023;13(2):101\u201321.","journal-title":"Am J Cardiovasc Dis"},{"issue":"1","key":"732_CR3","doi-asserted-by":"crossref","first-page":"e000304","DOI":"10.1136\/bmjdrc-2016-000304","volume":"5","author":"AC Hernandez-Romieu","year":"2017","unstructured":"Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009\u20132010. BMJ Open Diabetes Res Care. 2017;5(1):e000304.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"732_CR4","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"issue":"2","key":"732_CR5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","volume":"17","author":"SS Bailin","year":"2020","unstructured":"Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and weight gain in persons with HIV. Curr HIV\/AIDS Rep. 2020;17(2):138\u201350.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"732_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","volume":"73","author":"M Herrin","year":"2016","unstructured":"Herrin M, Tate JP, Akgun KM, Butt AA, Crothers K, Freiberg MS, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228\u201336.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"732_CR7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"732_CR8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","volume":"79","author":"DA Wohl","year":"2024","unstructured":"Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, et al. Antiretrovirals and weight change: weighing the evidence. Clin Infect Dis. 2024;79(4):999\u20131005.","journal-title":"Clin Infect Dis"},{"key":"732_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae238","author":"A Hill","year":"2024","unstructured":"Hill A, Tovar Sanchez T, Delaporte E, Sokhela S, Simmons B, Kouanfack C, et al. Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024;79(9):2369\u20132378.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"732_CR10","doi-asserted-by":"crossref","first-page":"ofz491","DOI":"10.1093\/ofid\/ofz491","volume":"6","author":"R Galdamez","year":"2019","unstructured":"Galdamez R, Garcia JA, Fernandez M, Robledano C, Agullo V, Garcia-Abellan J, et al. Short-term increase in risk of overweight and concomitant systolic blood pressure elevation in treatment-naive persons starting INSTI-based antiretroviral therapy. Open Forum Infect Dis. 2019;6(12):ofz491.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"732_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","volume":"18","author":"C Lagathu","year":"2019","unstructured":"Lagathu C, Bereziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9):829\u201340.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"732_CR12","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3018(24)00183-8","volume":"11","author":"N Pantazis","year":"2024","unstructured":"Pantazis N, Sabin CA, Grabar S, Van der Valk M, Jarrin I, van Sighem A, et al. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration. Lancet HIV. 2024;11(10):e660\u20139.","journal-title":"Lancet HIV"},{"issue":"8","key":"732_CR13","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/jac\/dky145","volume":"73","author":"DR Bakal","year":"2018","unstructured":"Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"732_CR14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267\u201374.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"732_CR15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/aid.2020.0197","volume":"37","author":"CD Lahiri","year":"2021","unstructured":"Lahiri CD, Xu Y, Wang K, Alvarez JA, Sheth AN, O\u2019Halloran J, et al. Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV. AIDS Res Hum Retroviruses. 2021;37(6):461\u20137.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"732_CR16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","volume":"73","author":"KM Erlandson","year":"2021","unstructured":"Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73(8):1440\u201351.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"732_CR17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"732_CR18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4102\/sajhivmed.v24i1.1500","volume":"24","author":"G Maartens","year":"2023","unstructured":"Maartens G, Sinxadi P, Venter WDF. Weight gain on dolutegravir: association is not the same as causation. South Afr J HIV Med. 2023;24(1):1500.","journal-title":"South Afr J HIV Med"},{"key":"732_CR19","unstructured":"Gilead Sciences. Biktarvy Prescribing information. 2024. https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf"},{"key":"732_CR20","unstructured":"European AIDS, October Clinical Society. Guidelines version 12. 2023. https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf"},{"issue":"1","key":"732_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral Society-USA panel. JAMA. 2023;329(1):63\u201384.","journal-title":"JAMA"},{"key":"732_CR22","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of health and human services. September 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"issue":"10107","key":"732_CR23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372.","journal-title":"Lancet"},{"issue":"10107","key":"732_CR24","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382.","journal-title":"Lancet"},{"key":"732_CR25","doi-asserted-by":"crossref","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir\/emtricitabine\/tenofovir Alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"732_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2011.10.006","volume":"166","author":"A De Lorenzo","year":"2013","unstructured":"De Lorenzo A, Bianchi A, Maroni P, Iannarelli A, Di Daniele N, Iacopino L, et al. Adiposity rather than BMI determines metabolic risk. Int J Cardiol. 2013;166(1):111\u20137.","journal-title":"Int J Cardiol"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00732-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T14:37:27Z","timestamp":1744036647000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00732-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00732-w","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both studies were undertaken in accordance with the Declaration of Helsinki and were approved by central or site-specific review boards or ethics committees. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data were partially previously presented as an oral presentation at IDWeek 2021 (virtual), September 29\u2013October 3, and in poster format at IDWeek 2022, October 19\u201323, Washington, DC, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"E.S.D. has received research support from Gilead Sciences, Inc. and ViiV Healthcare; and consultancy fees from Gilead Sciences, Inc., Genentech, and ViiV Healthcare. C.O. has received grants or contracts from ViiV Healthcare (paid to institution); speaker honoraria from Gilead Sciences, Inc., GSK, MSD, and ViiV Healthcare; and support for attending meetings and\/or travel from Gilead Sciences, Inc.; and is a governing council member of the International AIDS Society (unpaid). P.E.S. has received research support from Gilead Sciences, Inc., and ViiV Healthcare; and consultancy fees from AbbVie, Gilead Sciences, Inc., Merck, and ViiV Healthcare. D.H. has no conflicts of interest to disclose. A.P. has received grants or contracts from Gilead Sciences, Inc., and ViiV Healthcare (paid to institution); payment or honoraria for lectures, presentations, or educational events from Gilead Sciences, Inc., and ViiV Healthcare; and support for attending meetings and\/or travel from Gilead Sciences, Inc., and ViiV Healthcare; and is President of NEAT ID and a member of guideline committees for BHIVA and EACS. K.W. has received research support from Gilead Sciences, Inc. C.B. has received speaker honoraria from Gilead Sciences, Inc.; and support for attending meetings and\/or travel from Gilead Sciences, Inc. J.M.T. has received grants or contracts from MSD; consulting fees and speaker honoraria from Gilead Sciences, Inc., Janssen, MSD, and ViiV Healthcare; and support for attending meetings and\/or travel from Gilead Sciences, Inc., Janssen, and MSD; and has participated on a data safety monitoring board or advisory board for Gilead Sciences, Inc., Janssen, MSD, and ViiV Healthcare. H.L., C.D., C.C., S.M., and J.T.H. are employees of, and hold stock\/stock options in, Gilead Sciences, Inc. M.R. has received consulting fees from AbbVie, Gilead Sciences, Inc., Merck, and ViiV Healthcare; and speaker honoraria from AbbVie, Gilead Sciences, Inc., and ViiV Healthcare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}